We are presenting a poster named “Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay” at The Genetic Toxicology Association (GTA) Meeting 2025 held at the Clayton Hall Conference Center on the Campus of the University of Delaware in Newark from May 7 – 9, where we concluded that melatonin exhibited no evidence of genotoxic activity under a Bacterial Reverse Mutation Test, supporting its safety profile at the tested dose range. These findings contribute to the non-clinical safety assessment of melatonin as part of the IGC-AD1 development program.
